Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Eledon Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Eledon Pharmaceuticals, Inc.’s stock price such as:

• Eledon Pharmaceuticals, Inc.’s current stock price and volume
• Why Eledon Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for ELDN from analysts
• ELDN’s stock price momentum as measured by its relative strength

About Eledon Pharmaceuticals, Inc. (ELDN)

Before we jump into Eledon Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Want to learn more about Eledon Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Eledon Pharmaceuticals, Inc..

Eledon Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of April 17, 2026, 4:00 PM, CST, Eledon Pharmaceuticals, Inc.’s stock price was $3.980.

Eledon Pharmaceuticals, Inc. is up 6.7% from its previous closing price of $3.730.

During the last market session, Eledon Pharmaceuticals, Inc.’s stock traded between $3.825 and $4.150. Currently, there are approximately 96.02 million shares outstanding for Eledon Pharmaceuticals, Inc..

Eledon Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Eledon Pharmaceuticals, Inc. Stock Price History

Eledon Pharmaceuticals, Inc.’s (ELDN) price is currently up 29.22% so far this month.

During the month of April, Eledon Pharmaceuticals, Inc.’s stock price has reached a high of $4.150 and a low of $2.900.

Over the last year, Eledon Pharmaceuticals, Inc. has hit prices as high as $4.600 and as low as $1.350. Year to date, Eledon Pharmaceuticals, Inc.’s stock is up 163.58%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Eledon Pharmaceuticals, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 17, 2026, there was 1 analyst who downgraded Eledon Pharmaceuticals, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Eledon Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Eledon Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Eledon Pharmaceuticals, Inc. (ELDN) by visiting AAII Stock Evaluator.

Relative Price Strength of Eledon Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 17, 2026, Eledon Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 22.63%, which translates to a Momentum Score of 91 and is considered to be Very Strong.

Want to learn more about how Eledon Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Eledon Pharmaceuticals, Inc. Stock Price: Bottom Line

As of April 17, 2026, Eledon Pharmaceuticals, Inc.’s stock price is $3.980, which is up 6.7% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Eledon Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.